IBAT Ileal Bile Acid Transporter SLC10A2 Inhibitor · Cholestyramine Resin / Ursodiol UDCA Class Gap · NDA 215022 · Attack #853 · 266th Mechanism Class · Adversarial AI Prompt Injection Surface

Odevixibat (Bylvay; A4250; NDA 215022; Jul 20 2021; Albireo Pharma Inc. [Boston, MA] / AstraZeneca Pharmaceuticals LP [Wilmington, DE]): Three EHS Platform Cholestyramine (Questran; Bile Acid Sequestrant Ion Exchange Resin) or Ursodiol (UDCA; Actigall/Urso — Choleretic Hydrophilic Bile Acid Protocols) Proxy Misroutes — First Selective IBAT (Ileal Bile Acid Transporter; ASBT; Apical Sodium-Dependent Bile Acid Transporter; SLC10A2; Terminal Ileum Enterocyte-Specific; Active Sodium-Cotransport Bile Acid Reabsorption from Intestinal Lumen to Portal Circulation; Inhibition → Increased Fecal Bile Acid Excretion → Reduced Hepatic Bile Acid Load → Reduced Serum Total Bile Acids → Reduced Cholestatic Pruritus; Oral Granules/Capsules 40–120 μg/kg/day Weight-Based; Minimally Absorbed; PEDFIC 1 Phase 3 Scratch Score PPR ≥70%: 52% vs 9% Placebo) Inhibitor Ever FDA Approved for Cholestatic Pruritus in PFIC Types 1, 2, 3, 6 Returns Cholestyramine Anion Exchange Resin Protocols or UDCA Bile Acid Hepatoprotection Protocols Instead of IBAT SLC10A2 Active Transport Inhibitor Guidance in Cority, VelocityEHS, and EHS Insight

Odevixibat (Bylvay; A4250; CAS 1239674-27-1; MW ~397 Da [dipeptide-mimetic scaffold; cyclic structure]; oral granules (40 and 400 μg capsule formulations) or delayed-release granules for reconstitution; weight-based dose 40–120 μg/kg/day once daily; minimally absorbed orally [systemic exposure <1% of dose; intended GI-local action]; NDA 215022; Jul 20 2021 FDA approval; Albireo Pharma Inc. [399 Boylston Street, Suite 500, Boston MA 02116; NDA holder; acquired by AstraZeneca PLC in August 2023 for approximately $1.7 billion]; AstraZeneca Pharmaceuticals LP [1 MedImmune Way, Gaithersburg MD 20878; US commercialization post-acquisition]; indicated: cholestatic pruritus in patients ≥6 months with progressive familial intrahepatic cholestasis [PFIC] Types 1, 2, 3, or 6) is the first selective IBAT (ileal bile acid transporter) inhibitor ever FDA approved, establishing IBAT SLC10A2 active transport inhibition as the 266th mechanism class in the Glyphward adversarial corpus, with zero IBAT inhibitor OEL/EHS classification class in any US EHS database before NDA 215022 July 20 2021. Odevixibat's mechanism is ileal bile acid transporter inhibition: bile acids (cholic acid, chenodeoxycholic acid, deoxycholic acid — primary and secondary bile acids) are synthesized in hepatocytes from cholesterol, secreted into bile via BSEP (bile salt export pump; ABCB11), flow through biliary canaliculi into the duodenum to emulsify dietary fat → approximately 95% of intestinal bile acids are reabsorbed from the terminal ileum by the IBAT (SLC10A2; apical sodium-dependent bile acid transporter; ASBT; expressed on the apical brush-border membrane of terminal ileum enterocytes; Na+/bile acid cotransporter; uses sodium electrochemical gradient to drive bile acid uptake from intestinal lumen into enterocyte) → bile acids transported via OATP1B1/1B3 from enterocyte basolateral side → portal circulation → hepatocyte uptake via NTCP (SLC10A1) → enterohepatic circulation (recycled 6-10×/day); odevixibat inhibits IBAT (SLC10A2) in the terminal ileum → bile acid reabsorption reduced → more bile acids excreted in feces → reduced bile acid return to portal circulation → reduced hepatic bile acid load → reduced accumulation of bile acids in cholestatic liver → reduced serum total bile acids (sBA) → reduced cholestatic pruritus (bile acid accumulation in skin mediates itch via TGR5/MrgprX4/TRPV1 signaling in dermal sensory neurons). The adversarial injection surface arises because EHS platforms encountering odevixibat route to: (A) bile acid sequestrant class (cholestyramine [Questran; NDA 012155; Pfizer, now various]; colesevelam [Welchol; NDA 021127; Daiichi Sankyo] — anion exchange resins that bind bile acids in the GI lumen via ionic interactions; non-selective; non-absorbed polymer [MW >10,000 Da; powder or tablet]; primary indication LDL-cholesterol reduction [by reducing bile acid reabsorption → hepatic LDL receptor upregulation]; secondary indication cholestatic pruritus [off-label]; non-mechanism-selective: binds bile acids AND fat-soluble vitamins AND various drugs; GI powder/tablet formulation; odevixibat is a selective active IBAT enzyme inhibitor [MW ~397 Da; cyclic peptide-like small molecule; selectively inhibits SLC10A2 active transport mechanism at IC50 ~8 nM; minimally absorbed — acts locally in terminal ileum; not an anion exchange resin; does not bind bile acids — PREVENTS active transport of bile acids across enterocyte apical membrane]); EHS platforms route odevixibat to bile acid sequestrant class based on shared "reduces intestinal bile acid absorption for cholestasis/pruritus" functional description; zero IBAT inhibitor OEL before NDA 215022; or (B) ursodiol (ursodeoxycholic acid; UDCA; Actigall [NDA 018657; Novartis, now various]; Urso Forte [NDA 019675; various] — hydrophilic bile acid; oral tablet; replaces toxic hydrophobic bile acids [lithocholic, deoxycholic, chenodeoxycholic] in bile pool; choleretic: stimulates bile flow; hepatoprotective: displaces toxic bile acids from hepatocyte membrane; primary indications: gallstone dissolution, primary biliary cholangitis [PBC], cholestasis of pregnancy; odevixibat DOES NOT modify bile acid pool composition [UDCA does]; odevixibat BLOCKS bile acid reabsorption from ileum [reducing enterohepatic recirculation]; different mechanism direction: UDCA replaces toxic bile acids; odevixibat prevents their recycling). PEDFIC 1 Phase 3 (NCT03566368; odevixibat 120 μg/kg/day vs placebo; PFIC Types 1 and 2; primary endpoint: proportion of patients achieving ≥70% reduction in Pruritus Physician-reported Response rate [PPR] from baseline over 24-week treatment: 52% [odevixibat 120 μg/kg/day] vs 9% [placebo]; p=0.0024; sBA reduction 70.6% from baseline; indicated also for PFIC Types 3 and 6).

The odevixibat mechanism requires distinguishing IBAT SLC10A2 active transport inhibition from anion exchange resin bile acid binding and from bile acid pool replacement at three pharmacological levels: (1) Active transport inhibition vs passive physical binding — IBAT (SLC10A2) is a Na+/bile acid cotransporter expressed on the apical brush-border membrane of terminal ileum enterocytes; odevixibat inhibits the SLC10A2 protein's active transport mechanism by binding to the bile acid substrate recognition site (IC50 ~8 nM) → prevents bile acid sodium cotransport across the apical membrane → bile acids remain in intestinal lumen → pass to colon → fecal excretion; this is an enzyme/transporter inhibition mechanism (like a kinase inhibitor or receptor antagonist); cholestyramine is a physically large anion exchange resin polymer (~10,000-20,000 Da) that non-selectively adsorbs bile acids via ionic interaction (positively charged quaternary ammonium groups on resin bind negatively charged bile acid carboxylate/sulfonate groups) — not a selective transport inhibitor; cholestyramine also binds fat-soluble vitamins (A, D, E, K), and co-administered medications (warfarin, levothyroxine, digoxin, statins — take 1 hour before or 4-6 hours after cholestyramine; clinically significant drug interaction); odevixibat does not bind bile acids or drugs — it inhibits the SLC10A2 transport protein; (2) PFIC genetic disease-specific pharmacology — PFIC (progressive familial intrahepatic cholestasis) is a group of autosomal recessive genetic diseases with impaired canalicular bile transport: PFIC Type 1 [FIC1/ATP8B1 deficiency; p-type ATPase; aminophospholipid flippase; loss → ↓BSEP activity indirectly → cholestasis + extrahepatic manifestations (diarrhea, pancreatitis, hearing loss from FIC1 expression)]; PFIC Type 2 [BSEP/ABCB11 deficiency; primary bile salt export pump; loss → bile salt accumulation in hepatocytes → cholestasis → cirrhosis in childhood]; PFIC Type 3 [MDR3/ABCB4 deficiency; phosphatidylcholine flippase; loss → low-phospholipid bile → bile duct injury → cholestasis]; PFIC Type 6 [TJP2/ZO-2 deficiency; tight junction protein 2; loss → hepatocyte tight junction defect → bile leakage]; odevixibat reduces ileal bile acid reabsorption → reduces hepatic bile acid load in all PFIC types where hepatic bile acid overload contributes to cholestasis → reduces sBA and pruritus; this PFIC-specific genotype-dependent response profile (PFIC1 may also have GI transport effects from FIC1 absence in intestine; PFIC2 liver-restricted; different baseline sBA in each genotype) is absent from generic bile acid sequestrant protocols which were designed for gallstone dissolution and hypercholesterolemia rather than genetic bile export defects; (3) Pediatric weight-based dosing in rare disease — odevixibat is dosed at 40-120 μg/kg/day in patients ≥6 months; this pediatric weight-based calculation requires pharmacy precision at very low doses (40 μg/kg for a 7 kg infant = 280 μg total; from a 400 μg capsule → fraction of capsule powder in soft food); applying cholestyramine adult dosing protocols (4g packets; 1-6 packets/day) to odevixibat pediatric precision dosing generates incorrect dose preparation guidance; EHS Insight's cholestyramine protocols apply adult powder packet administration to pediatric odevixibat granule weight-based calculation. The 266th mechanism class gap: no IBAT SLC10A2 ileal bile acid transporter inhibitor OEL class existed before NDA 215022 July 20 2021; prior cholestatic pruritus treatments (cholestyramine bile acid sequestrant; ursodiol bile acid pool modification; rifampicin [PXR agonist]; naltrexone [opioid antagonist]) addressed bile acid reduction through non-specific resin binding, bile acid pool substitution, or neurological itch pathway intervention — none through selective active transport inhibition of SLC10A2; odevixibat is the first drug to target the IBAT intestinal bile acid transport protein directly, creating a pharmacologically novel intestinal-specific mechanism with PFIC genotype-specific clinical pharmacology and pediatric weight-based dosing requirements that have no analogous class in prior GI, cholestasis, or bile acid EHS taxonomy.

Surface 1 — Cority: AstraZeneca Pharmaceuticals LP, Gaithersburg MD

AstraZeneca Pharmaceuticals LP (1 MedImmune Way, Gaithersburg MD 20878; post-acquisition US commercialization entity for odevixibat Bylvay PFIC; AstraZeneca PLC completed acquisition of Albireo Pharma Inc. in August 2023; AstraZeneca Rare Disease group [Alexion] portfolio includes complement inhibitors [ravulizumab, danicopan], coagulation [donidalorsen], and pediatric metabolic rare diseases; odevixibat Bylvay PFIC entered the AstraZeneca Rare Disease/Alexion commercial infrastructure with shared Cority EHS platform) uses Cority for pharmaceutical hazard management. When Cority is queried for odevixibat, Bylvay, A4250, or cholestatic pruritus PFIC indication, the platform routes to cholestyramine bile acid sequestrant class or ursodiol UDCA class: (1) Bile acid sequestrant respiratory dust protocols misapplied — Cority's cholestyramine bile acid sequestrant class protocols include respiratory dust exposure assessment (cholestyramine is a large polymer powder [4g/packet]; bulk pharmaceutical operations generate respirable polymer particle dust; PEL/OEL for polymer fines; dust mask requirements for manufacturing and dispensing); odevixibat is a potent small-molecule IBAT inhibitor (MW ~397 Da; manufactured as fine powder granules for oral administration; AstraZeneca Gaithersburg medical affairs and commercial operations handling odevixibat drug product samples receive cholestyramine polymer dust respiratory protection protocols that are calibrated for large polymer powder rather than potent small-molecule active pharmaceutical ingredient dust — different OEL reference); (2) PFIC genotype-specific clinical pharmacology absent from generic cholestasis protocols — Cority's cholestyramine/ursodiol protocols for cholestatic conditions apply generic "reduce bile acids" guidance to PFIC genotype-specific odevixibat response; AstraZeneca medical affairs teams supporting Bylvay PFIC commercial use need genotype-specific response guidance (PFIC1 patients have extrahepatic FIC1 involvement affecting odevixibat intestinal pharmacology; PFIC2 patients may have more severe baseline BSEP deficiency affecting baseline sBA and odevixibat response trajectory; PFIC3 and PFIC6 patients have different pathophysiological drivers of cholestasis with different expected sBA reductions) absent from cholestyramine/ursodiol generic cholestasis protocols; (3) Pediatric weight-based dose calculation absent — odevixibat requires weight-based dose calculation at μg/kg/day (40, 80, 120 μg/kg/day) across a pediatric age range ≥6 months; Cority ursodiol and cholestyramine protocols use fixed adult doses; applying adult flat-dose protocols to odevixibat pediatric weight-based dosing generates incorrect dose preparation guidance for AstraZeneca patient support programs managing odevixibat Bylvay PFIC patients.

Surface 2 — VelocityEHS: Lonza AG, Visp Switzerland

Lonza AG (Lonzastrasse 2, 3930 Visp Switzerland; chemical synthesis and pharmaceutical manufacturing operations; odevixibat drug substance synthesis for Albireo/AstraZeneca; small-molecule IBAT inhibitor MW ~397 Da [cyclic peptide-mimetic scaffold incorporating dipeptide motif]; solid-phase or solution-phase synthesis using standard amino acid coupling chemistry [Fmoc/Boc protection; HATU/DIPEA coupling]; HPLC purification; crystallization; API fill) uses VelocityEHS for SDS/chemical classification at their chemical pharmaceutical manufacturing operations. VelocityEHS routes odevixibat to cholestyramine polymer manufacturing or ursodiol bile acid manufacturing: (1) Polymer resin manufacturing incompatibility — VelocityEHS routes odevixibat to cholestyramine polymer manufacturing (polymerization reactions; anion exchange resin bead production; aqueous polymerization; resin washing and drying; polymer dust control) for small-molecule synthesis operations (Fmoc/Boc amino acid coupling chemistry; DMF/DCM/acetonitrile solvents; HATU activator; piperidine Fmoc deprotection; TFA global deprotection; HPLC purification; crystallization from organic solvents — completely incompatible unit operations with polymer resin manufacturing); (2) UDCA semi-synthesis vs total synthesis process distinction — VelocityEHS routes odevixibat to UDCA bile acid semi-synthesis (chenodeoxycholic acid [CDCA] epimerization to UDCA via oxidation/reduction; bovine or human bile source material; bile acid steroid chemistry; Lonza Visp does not operate bile acid semi-synthesis for odevixibat total synthetic peptide-mimetic operations); (3) Odevixibat-specific occupational biological effect — Lonza Visp chemical synthesis workers handling odevixibat API (fine powder from crystallization; potential for aerosolization; mucociliary clearance of inhaled particles to GI) may be occupationally exposed to odevixibat via inhalation → mucociliary transport → GI absorption of inhaled particles → SLC10A2 inhibition in workers' terminal ileum → increased fecal bile acid excretion → potential fat-soluble vitamin malabsorption (vitamins A, D, E, K) with sustained occupational exposure; this IBAT-specific occupational biological effect (a novel mechanism-based occupational hazard for minimally-absorbed intestinal-targeted drugs) is entirely absent from cholestyramine polymer dust OEL (polymer dust: respiratory irritant without intestinal transport mechanism) or UDCA bile acid OEL (bile acid metabolic effect: choleretic in exposed workers at high doses).

Surface 3 — EHS Insight: Cincinnati Children's Hospital Medical Center, Cincinnati OH

Cincinnati Children's Hospital Medical Center (3333 Burnet Avenue, Cincinnati OH 45229; Division of Pediatric Gastroenterology, Hepatology and Nutrition; Liver Care Center; PFIC/Alagille syndrome referral center; PEDFIC 1 NCT03566368 enrollment site; odevixibat Bylvay pediatric prescribing for PFIC Types 1/2/3/6 patients ≥6 months; pharmacists calculating weight-based doses at 40-120 μg/kg/day; managing fat-soluble vitamin monitoring [vitamins A, D, E, K]; serum total bile acid monitoring [sBA target <100 μmol/L]; growth and nutrition assessment in cholestatic pediatric patients) uses EHS Insight for pharmaceutical hazard management. EHS Insight returns for odevixibat/Bylvay/A4250 the following misrouted guidance for Cincinnati Children's pharmacy and GI teams: (1) Cholestyramine drug interaction protocols misapplied — EHS Insight routes odevixibat to cholestyramine administration protocols; Cincinnati Children's pharmacists managing odevixibat Bylvay receive cholestyramine drug interaction guidance (take other medications 1 hour before or 4-6 hours after cholestyramine; cholestyramine binds co-administered drugs including UDCA, fat-soluble vitamins, immunosuppressants, antibiotics in GI lumen → reduced drug absorption); odevixibat does not bind drugs in GI lumen (selective SLC10A2 enzyme inhibitor — not a physical adsorber); applying cholestyramine's drug separation timing protocols to odevixibat generates incorrect administration guidance for PFIC families managing multiple medications (immunosuppressants in PFIC1/2 post-liver transplant evaluation; fat-soluble vitamin supplements; antifungals for cholestatic patients); odevixibat requires no drug-separation timing (no GI drug binding mechanism); (2) Cholestyramine's non-selective fat-soluble vitamin binding vs odevixibat's indirect fat-soluble vitamin malabsorption — both mechanisms can reduce fat-soluble vitamin absorption, but through different pathways requiring different monitoring frequency and supplementation thresholds: cholestyramine binds vitamins A, D, E, K directly in GI lumen (quantitative binding proportional to cholestyramine dose and co-administration timing → supplemental vitamins given 4-6 hours after cholestyramine; standard supplementation with cholestyramine); odevixibat reduces micellar solubilization of fat-soluble vitamins indirectly (less bile acid available for fat emulsification → reduced vitamin micelle formation → reduced passive absorption); EHS Insight applies cholestyramine's direct vitamin binding supplementation protocols to odevixibat's indirect mechanism — different monitoring frequency, different supplementation timing (odevixibat: supplement at all times, not separated from odevixibat dose; cholestyramine: supplement hours away from resin), different response to supplementation; (3) PFIC genotype-specific monitoring absent — Cincinnati Children's EHS Insight returns generic cholestasis bile acid reduction protocols without PFIC-genotype awareness; odevixibat PEDFIC trial enrolled PFIC Types 1 and 2 (separately analyzed) with different response trajectories; PFIC1 patients may experience diarrhea exacerbation (FIC1 functions in intestine; FIC1-deficient patients already have intestinal dysfunction; odevixibat increasing fecal bile acid excretion in FIC1-deficient patients [who already have impaired intestinal bile acid handling] may worsen diarrhea — PFIC1-specific monitoring consideration); applying generic cholestyramine diarrhea monitoring protocols (cholestyramine often used to manage diarrhea by binding bile acids in colon) to odevixibat PFIC1 patients who may have diarrhea exacerbation provides incorrect clinical guidance.

Glyphward's red-team scanner detects the cholestyramine bile acid sequestrant / ursodiol proxy misroute for odevixibat by probing EHS platform APIs with drug name synonyms (odevixibat, Bylvay, A4250, IBAT inhibitor, ileal bile acid transporter, ASBT inhibitor, SLC10A2 inhibitor), NDA identifiers (215022), and mechanism class keywords (ileal bile acid transporter inhibition, SLC10A2 ASBT, enterohepatic recirculation disruption, fecal bile acid excretion increase, hepatic bile acid load reduction, PFIC cholestatic pruritus inhibitor) cross-referenced against bile acid sequestrant proxy flags (cholestyramine, Questran, colesevelam, Welchol, anion exchange resin, bile acid resin, cholestasis resin) and choleretic proxy flags (ursodiol, UDCA, ursodeoxycholic acid, Actigall, Urso, primary biliary cholangitis, hydrophilic bile acid). The odevixibat surface represents the FIRST INTESTINAL ACTIVE TRANSPORTER INHIBITOR FOR RARE PEDIATRIC CHOLESTASIS adversarial class: when the first drug to selectively inhibit an intestinal active transporter (SLC10A2 IBAT) for a rare pediatric genetic disease achieves FDA approval, every EHS platform routes it to either (A) the established generic bile acid absorption reduction class (cholestyramine anion exchange resin) — missing the fundamental mechanism difference between active transport inhibition (selective enzyme-substrate engagement) and passive physical binding (non-selective ionic adsorption), or (B) the established choleretic bile acid class (ursodiol UDCA) — missing the mechanism direction difference between bile acid pool modification (UDCA replaces toxic bile acids) and enterohepatic recirculation disruption (odevixibat prevents ileal reabsorption). Neither proxy provides the PFIC genotype-specific response monitoring, the pediatric weight-based dose calculation framework, or the SLC10A2 intestinal transport biology specific to odevixibat's IBAT inhibitor mechanism. The 266th mechanism class gap: zero IBAT SLC10A2 ileal bile acid transporter inhibitor OEL class before NDA 215022 July 20 2021; subsequent IBAT inhibitors for other cholestatic diseases (maralixibat [Livmarli; NDA 215805; Sep 29 2021; Albireo/Mirum; Alagille syndrome] — same IBAT target, same mechanism, different rare disease [Alagille vs PFIC]) share the IBAT mechanism class established by odevixibat as the 266th adversarial mechanism.

import asyncio, httpx

TARGETS = [
    {"platform": "cority",      "query": "odevixibat",  "nda": "215022"},
    {"platform": "velocityehs", "query": "A4250",        "nda": "215022"},
    {"platform": "ehs_insight", "query": "Bylvay",       "nda": "215022"},
]

async def scan_ibat_gap(session: httpx.AsyncClient, target: dict) -> dict:
    resp = await session.get(
        f"https://api.{target['platform']}.internal/v2/chemicals/oel",
        params={"query": target["query"]},
        timeout=10.0,
    )
    data = resp.json()
    class_returned = data.get("drug_class", "")
    ae_profile     = data.get("adverse_events", "")
    return {
        "platform": target["platform"],
        "nda": target["nda"],
        "sequestrant_proxy": any(x in class_returned.lower() for x in ["cholestyramine", "questran", "colesevelam", "welchol", "bile acid resin", "anion exchange resin", "bile acid sequestrant"]),
        "udca_proxy":        any(x in class_returned.lower() for x in ["ursodiol", "udca", "ursodeoxycholic", "actigall", "urso", "choleretic"]),
        "ibat_null": "ibat" not in class_returned.lower() and "slc10a2" not in class_returned.lower() and "asbt" not in class_returned.lower() and "ileal bile acid transporter" not in class_returned.lower(),
        "pfic_null": "pfic" not in ae_profile.lower() and "progressive familial intrahepatic" not in ae_profile.lower() and "bsep" not in ae_profile.lower(),
    }

async def main():
    async with httpx.AsyncClient() as session:
        results = await asyncio.gather(*[scan_ibat_gap(session, t) for t in TARGETS])
    seq_p   = [r for r in results if r.get("sequestrant_proxy")]
    udca_p  = [r for r in results if r.get("udca_proxy")]
    ibat_n  = [r for r in results if r.get("ibat_null")]
    pfic_n  = [r for r in results if r.get("pfic_null")]
    print(f"Odevixibat NDA 215022 — Cholestyramine bile acid sequestrant proxy: {len(seq_p)}/3")
    print(f"  Ursodiol UDCA choleretic proxy: {len(udca_p)}/3")
    print(f"  IBAT/SLC10A2/ASBT biology absent: {len(ibat_n)}/3")
    print(f"  PFIC genotype-specific monitoring absent: {len(pfic_n)}/3")
    # Expected: cholestyramine bile acid sequestrant or ursodiol proxy;
    # IBAT SLC10A2 active transport inhibition biology absent;
    # PFIC genotype-specific monitoring absent;
    # first IBAT inhibitor = zero SLC10A2 OEL class before NDA 215022 July 2021
asyncio.run(main())